BioVie Inc. (BIVI) Income Statement
BIVI FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsBIVI revenue and net income
BIVI growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BIVI quarterly EPS vs estimates
BioVie beat the analyst EPS estimate in 2 of the last 6 quarters. Next report: November 9, 2026.
BIVI income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $229,377 | $229,377 | $266,842 | $237,421 | $229,377 | $229,377 | $229,377 | $229,377 | $229,377 |
| Gross profit | — | −$229,377 | −$229,377 | −$266,842 | −$237,421 | −$229,377 | −$229,000 | −$229,000 | −$229,000 | −$229,000 |
| Research & development | $14.0M | $9.3M | $23.1M | $33.3M | $17.3M | $133.2M | $1.2M | $1.0M | $370,853 | $466,354 |
| Sales, general & admin | $8.5M | $8.6M | $8.8M | $11.6M | $9.8M | $4.6M | $1.3M | $1.3M | $1.8M | $857,883 |
| Total operating expenses | $22.7M | $17.8M | $32.2M | $45.1M | $27.3M | $138.1M | $2.7M | $2.5M | $2.4M | $1.6M |
| Operating income | −$22.7M | −$18.1M | −$32.2M | −$45.1M | −$27.3M | −$138.1M | −$2.7M | −$2.5M | −$2.4M | −$1.6M |
| Interest income | $596,771 | $853,029 | $1.1M | $562,264 | $44,080 | $21,971 | $234 | $1,159 | $4 | $14 |
| Interest expense | $17,901 | $332,720 | $2.9M | $4.3M | $2.2M | $559,455 | $4.8M | $273 | $40,960 | $222,942 |
| Income before taxes | −$22.1M | −$17.5M | −$32.1M | −$50.3M | −$26.1M | −$130.2M | −$16.7M | −$2.4M | −$2.4M | −$1.3M |
| Income taxes | — | — | −$229,377 | $4.3M | −$3.3M | $559,455 | $4.8M | −$51,400 | −$1 | −$223,000 |
| Net income | −$22.1M | −$17.5M | −$32.1M | −$50.3M | −$26.1M | −$130.2M | −$16.7M | −$2.4M | −$2.4M | −$1.3M |
| EBITDA | −$21.9M | −$17.0M | −$29.0M | −$45.7M | −$23.7M | −$129.5M | −$2.5M | −$2.3M | −$2.1M | −$1.3M |
| EPS (diluted) | −$3.14 | −$17.85 | −$71.80 | −$154.00 | −$50.56 | −$1066.05 | −$7.52 | −$1.04 | −$2.49 | −$2.25 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $6,308 | $57,344 | $57,344 | $57,344 | $57,344 | $57,344 | $57,344 | $57,344 | $57,344 | $57,344 | $57,344 | $67,385 |
| Gross profit | −$6,308 | −$57,344 | −$57,344 | −$57,344 | −$57,344 | −$57,344 | −$57,344 | −$57,344 | −$57,344 | −$57,344 | −$57,344 | −$67,385 |
| Research & development | $3.6M | $3.2M | $4.3M | $2.9M | $1.2M | $1.3M | $4.7M | $2.0M | $2.1M | $5.7M | $6.5M | $8.9M |
| Sales, general & admin | $6.3M | $2.2M | $1.9M | $2.3M | $2.4M | $1.6M | $2.5M | $2.1M | $2.7M | $2.0M | $2.3M | $1.9M |
| Total operating expenses | $5.7M | $5.3M | $6.2M | $5.2M | $3.6M | $3.0M | $7.3M | $4.1M | $4.7M | $7.7M | $8.8M | $10.9M |
| Operating income | −$5.7M | −$5.4M | −$6.3M | −$5.3M | −$3.7M | −$3.0M | −$7.3M | −$4.1M | −$4.8M | −$7.7M | −$8.8M | −$10.9M |
| Interest income | $77,902 | $121,045 | $198,797 | $199,027 | $178,942 | $197,494 | $253,036 | $223,557 | $272,517 | $183,933 | $218,029 | $462,223 |
| Interest expense | $3,978 | $5,967 | $5,967 | $1,989 | $4,998 | $4,998 | $66,700 | $256,024 | $439,943 | $628,711 | $820,600 | $1.0M |
| Income before taxes | −$5.6M | −$5.3M | −$6.1M | −$5.1M | −$3.5M | −$2.8M | −$7.1M | −$4.2M | −$4.9M | −$8.1M | −$8.4M | −$10.7M |
| Income taxes | — | — | — | — | $7.2M | — | −$7.2M | −$4.5M | $439,943 | −$4 | $820,600 | $1.0M |
| Net income | −$5.6M | −$5.3M | −$6.1M | −$5.1M | −$3.5M | −$2.8M | −$7.1M | −$4.2M | −$4.9M | −$8.1M | −$8.4M | −$10.7M |
| EBITDA | −$5.7M | −$5.2M | −$6.0M | −$5.1M | −$3.4M | −$2.7M | −$7.0M | −$3.8M | −$4.4M | −$7.4M | −$7.5M | −$9.6M |
| EPS (diluted) | −$0.70 | −$0.70 | −$0.77 | −$0.98 | −$11.05 | −$1.50 | −$4.60 | −$0.70 | −$0.80 | −$20.00 | −$22.00 | −$29.00 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BIVI's financial statements (latest annual report filed August 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BIVI financial results
BioVie reported no revenue in fiscal year 2026 (ended June 30, 2026). It had a net loss of $22.1 million. Diluted earnings per share came to −$3.14.
See the BIVI stock overview for the latest quote and news, or the BIVI chart for price history and technical indicators.
BIVI income statement FAQ
Does BioVie have revenue?
BioVie reported no revenue for fiscal year 2026, which ended on June 30, 2026.
Is BioVie profitable?
No. BioVie reported a net loss of $22.1 million in fiscal 2026.
How much does BioVie spend on research and development?
BioVie spent $14.0 million on research and development in fiscal 2026.
What are BioVie's earnings per share?
BioVie earned $-3.14 per diluted share in fiscal 2026, compared with $-17.85 a year earlier.
When will BioVie report its next earnings?
BioVie is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes.
When does BioVie's fiscal year end?
BioVie's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on August 13, 2026.